EODData

MEMBERSHIP REGISTER LOG IN

FRA, UP0: Ultragenyx Pharmaceutical Inc

09 Jan 2026
LAST:

19.80

CHANGE:
 0.80		OPEN:
19.80		HIGH:
19.80		ASK:
0.00		VOLUME:
417
CHG(%):
3.88		PREV:
20.60		LOW:
19.80		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
09 Jan 2619.8019.8019.8019.80417
08 Jan 2620.6020.6020.6020.60417
07 Jan 2619.1019.1019.1019.10417
06 Jan 2619.6019.6019.6019.60417
05 Jan 2620.2020.2020.2020.20417
02 Jan 2619.4019.4019.4019.40417
30 Dec 2516.8017.3016.8017.00417
29 Dec 2528.8028.8028.8028.8060
23 Dec 2529.2029.2029.2029.2060

PROFILE

Name:Ultragenyx Pharmaceutical Inc
About:Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Sector:Healthcare
Industry:Biotechnology
Address:60 Leveroni Court, Novato, CA, United States, 94949
Website:https://www.ultragenyx.com
ISIN:US90400D1081
LEI:529900EV44GVDN1DCX77

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-4.64 
Forward P/E:-5.09 
PEG Ratio:-5.09 
Price to Sales:4.57 
Price to Book:361.83 
Profit Margin:-0.92 
Operating Margin:-1.07 
Return on Assets:-0.25 
Return on Equity:-3.13 
Revenue:535.69M 
Shares:96.37M 
Market Cap:1.908B 

TECHNICAL INDICATORS

MA5:19.860.3%
MA10:22.2112.2%
MA20:26.3333.0%
MA50:27.6439.6%
MA100:26.6934.8%
MA200:28.5344.1%
STO9:22.95
STO14:20.59
RSI14:26.29 
WPR14:-78.79
MTM14:-10.40
ROC14:-0.34 
ATR:1.67 
Week High:20.604.0%
Week Low:19.103.7%
Month High:31.4058.6%
Month Low:16.8044.1%
Year High:43.84121.4%
Year Low:16.8017.9%
Volatility:17.06